Temozolomide in the treatment of solid tumours: current results and rationale for dosing/scheduling.
about
Genotoxic anti-cancer agents and their relationship to DNA damage, mitosis, and checkpoint adaptation in proliferating cancer cellsConcomitant treatment of brain metastasis with whole brain radiotherapy [WBRT] and temozolomide [TMZ] is active and improves quality of lifeBrain Radiotherapy plus Concurrent Temozolomide versus Radiotherapy Alone for Patients with Brain Metastases: A Meta-Analysis.Mutation signatures of carcinogen exposure: genome-wide detection and new opportunities for cancer prevention.A phase II study of thalidomide and temozolomide in patients with brain metastases from malignant melanoma: lymphopenia correlates with response.Metronomic treatment of temozolomide increases anti-angiogenicity accompanied by down-regulated O(6)-methylguanine-DNA methyltransferase expression in endothelial cells.NF-κB is activated in response to temozolomide in an AKT-dependent manner and confers protection against the growth suppressive effect of the drug.A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancerRecurrent glioblastoma multiforme: advances in treatment and promising drug candidates.Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft models.New developments in the treatment of malignant gliomas.Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model.Preparation of Temozolomide-Loaded Nanoparticles for Glioblastoma Multiforme Targeting-Ideal Versus Reality.Amino acid Asp181 of 5'-flap endonuclease 1 is a useful target for chemotherapeutic development.Insights into pharmacotherapy of malignant glioma in adults.Combination hyperbaric oxygen and temozolomide therapy in C6 rat glioma model.Cell cycle effects and increased adduct formation by temozolomide enhance the effect of cytotoxic and targeted agents in lung cancer cell lines.O-methylguanine-DNA methyltransferase immunoexpression in a double pituitary adenoma: case report.Minimally cytotoxic doses of temozolomide produce radiosensitization in human glioblastoma cells regardless of MGMT expression.Use of temozolomide in aggressive pituitary tumors: case report.A phase II study of thalidomide in patients with brain metastases from malignant melanoma.
P2860
Q26851196-EE058B05-7A64-4F55-BE55-83347AE07AD6Q33270398-851A57DC-73B5-417B-B31C-FD2EBEFE2F77Q33430404-819181D2-3161-44C0-8E37-7BA8D4A9F0E5Q33772624-E4F02579-FF9F-4751-A124-17F1C2B4EA3CQ35602183-916A4915-A4B8-4373-87B8-3C7B7FAFAE84Q36230477-BE249B37-6B54-47EC-AF47-5C06C4943201Q36552658-A2E4B150-3F29-4A09-8E10-450F5839B310Q36667516-8858E860-C66A-4D49-9444-F9ADBFB100EEQ36668246-4C22A095-3803-471D-8F39-E29717F938A9Q36866006-DE63777F-6087-4928-8789-2A26E648E093Q36972696-2E66F77C-2F52-48E5-83D7-5ADAA2ADA326Q37284263-A46262AB-D2A4-4457-ACA4-3C16E7E68E36Q37290850-098FD022-D764-4302-981E-961A76211E61Q37474607-208F6691-42A1-4EC2-BBBA-C20D5F9C543BQ37575528-732E7DB5-C44E-47B5-B606-BE64BDB9450FQ39336771-D6C4B151-BB85-43FC-9FBD-400080470617Q39830999-A9B44050-E82D-491F-B4B3-9629C0DD8C9BQ39908548-95440F4B-4814-4032-98B1-89A6B3189143Q40538138-3C15ED84-D2AA-4D01-9939-C73794DBAD1BQ46059407-FFCD11D5-9D2E-46CD-B907-2F88047FE88AQ46496647-CDC34218-E21E-4A81-9F3A-A01BAABD8BD9
P2860
Temozolomide in the treatment of solid tumours: current results and rationale for dosing/scheduling.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Temozolomide in the treatment ...... tionale for dosing/scheduling.
@ast
Temozolomide in the treatment ...... tionale for dosing/scheduling.
@en
type
label
Temozolomide in the treatment ...... tionale for dosing/scheduling.
@ast
Temozolomide in the treatment ...... tionale for dosing/scheduling.
@en
prefLabel
Temozolomide in the treatment ...... tionale for dosing/scheduling.
@ast
Temozolomide in the treatment ...... tionale for dosing/scheduling.
@en
P2093
P1476
Temozolomide in the treatment ...... tionale for dosing/scheduling.
@en
P2093
M R Middleton
S E Pratap
P304
P356
10.1016/J.CRITREVONC.2004.10.004
P577
2005-03-01T00:00:00Z